BRPI0411114A - solução aquosa estável de eritropoetina humana, não contendo albumina de soro - Google Patents

solução aquosa estável de eritropoetina humana, não contendo albumina de soro

Info

Publication number
BRPI0411114A
BRPI0411114A BRPI0411114-1A BRPI0411114A BRPI0411114A BR PI0411114 A BRPI0411114 A BR PI0411114A BR PI0411114 A BRPI0411114 A BR PI0411114A BR PI0411114 A BRPI0411114 A BR PI0411114A
Authority
BR
Brazil
Prior art keywords
human erythropoietin
serum albumin
aqueous solution
stable aqueous
containing serum
Prior art date
Application number
BRPI0411114-1A
Other languages
English (en)
Inventor
Kyu Chan Kwon
Suk Young Choi
Young Cheol Kang
Hoon Sung Jeh
Seung Joo Lee
Myung Jin Kim
Ji Eon Kim
Jin-Seok Oh
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0411114(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of BRPI0411114A publication Critical patent/BRPI0411114A/pt
Publication of BRPI0411114B1 publication Critical patent/BRPI0411114B1/pt
Publication of BRPI0411114B8 publication Critical patent/BRPI0411114B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"SOLUçãO AQUOSA ESTáVEL DE ERITROPOETINA HUMANA, NãO CONTENDO ALBUMINA DE SORO". A presente invenção fornece uma formulação aquosa de eritropoetina humana tendo a estabilidade de armazenamento após um longo período sem albumina de soro, em que a formulação compreende uma quantidade farmaceuticamente eficaz de eritropoetina humana; tensoativo não-iónico, álcool poliídrico, aminoácido neutro e álcool de açúcar como estabilizadores; reagente isotónico; e reagente tampão.
BRPI0411114A 2003-06-10 2004-06-07 solução aquosa estável de eritropoetina humana, não contendo albumina de soro BRPI0411114B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2003-0037060 2003-06-10
KR20030037060 2003-06-10
PCT/KR2004/001358 WO2004108152A1 (en) 2003-06-10 2004-06-07 Stable, aqueous solution of human erythropoietin, not containing serum albumin

Publications (3)

Publication Number Publication Date
BRPI0411114A true BRPI0411114A (pt) 2006-07-18
BRPI0411114B1 BRPI0411114B1 (pt) 2020-09-15
BRPI0411114B8 BRPI0411114B8 (pt) 2021-05-25

Family

ID=36337525

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411114A BRPI0411114B8 (pt) 2003-06-10 2004-06-07 solução aquosa estável de eritropoetina humana, não contendo albumina de soro

Country Status (19)

Country Link
US (1) US8119595B2 (pt)
EP (1) EP1641486B1 (pt)
JP (1) JP4871720B2 (pt)
KR (1) KR100610003B1 (pt)
CN (1) CN1802171B (pt)
AT (1) ATE553747T1 (pt)
AU (1) AU2004244920B2 (pt)
BR (1) BRPI0411114B8 (pt)
CA (1) CA2528988C (pt)
EA (1) EA009676B1 (pt)
ES (1) ES2385888T3 (pt)
HK (1) HK1093012A1 (pt)
MX (1) MXPA05013398A (pt)
NO (1) NO20055747L (pt)
NZ (1) NZ543859A (pt)
PL (1) PL379272A1 (pt)
UA (1) UA82241C2 (pt)
WO (1) WO2004108152A1 (pt)
ZA (1) ZA200509222B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
WO2007108505A1 (ja) * 2006-03-22 2007-09-27 Chugai Seiyaku Kabushiki Kaisha エリスロポエチン溶液製剤
DE102007050165B4 (de) * 2007-10-19 2010-06-17 Stiftung Tierärztliche Hochschule Hannover Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung
EP3381445B1 (en) * 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
HUE049023T2 (hu) * 2008-08-15 2020-08-28 Ironwood Pharmaceuticals Inc Linaklotidot tartalmazó, szájon át történõ beadásra szolgáló készítmények
WO2011017502A2 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
WO2011090306A2 (en) * 2010-01-19 2011-07-28 Hanmi Holdings Co., Ltd Liquid formulations for long-acting erythropoietin conjugate
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
RS59978B1 (sr) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals Inc Stabilne formulacije linaklotida
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
DK2776055T3 (en) 2011-08-17 2017-03-06 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
RU2015143521A (ru) * 2013-03-13 2017-04-19 Илэвэн Байотерапьютикс, Инк. Лекарственные формы химерных цитокинов для глазной доставки
EP2832361A1 (en) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Aqueous sustained release compositions of LHRH analogs
DK3287141T3 (da) * 2015-04-21 2021-10-11 Staidson Beijing Biopharmaceuticals Co Ltd Nervevækstfaktorsammensætning og injektionspulver
WO2023098844A1 (zh) * 2021-12-03 2023-06-08 杰科（天津）生物医药有限公司 一种制剂及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
GB9001987D0 (en) 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
CA2319672C (en) * 1997-02-07 2011-01-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
WO2000015241A1 (fr) * 1998-09-11 2000-03-23 Chugai Seiyaku Kabushiki Kaisha Preparation d'une solution proteinique et son procede de stabilisation
CA2369444C (en) 1999-04-09 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Pharmaceutical compositions of erythropoietin
AU6875900A (en) * 1999-09-08 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
AU2001236005A1 (en) * 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
EP1525889A1 (en) * 2000-05-15 2005-04-27 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivative
SI21258A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol

Also Published As

Publication number Publication date
JP2007528842A (ja) 2007-10-18
NZ543859A (en) 2008-01-31
EP1641486A4 (en) 2008-10-08
PL379272A1 (pl) 2006-08-21
BRPI0411114B1 (pt) 2020-09-15
CN1802171B (zh) 2010-10-13
MXPA05013398A (es) 2006-03-09
AU2004244920A1 (en) 2004-12-16
US20070293419A1 (en) 2007-12-20
EP1641486B1 (en) 2012-04-18
UA82241C2 (uk) 2008-03-25
EA009676B1 (ru) 2008-02-28
AU2004244920B2 (en) 2009-07-23
US8119595B2 (en) 2012-02-21
CA2528988C (en) 2012-05-01
CN1802171A (zh) 2006-07-12
KR20040110994A (ko) 2004-12-31
EP1641486A1 (en) 2006-04-05
CA2528988A1 (en) 2004-12-16
HK1093012A1 (en) 2007-02-23
WO2004108152A1 (en) 2004-12-16
ES2385888T3 (es) 2012-08-02
NO20055747L (no) 2006-03-07
NO20055747D0 (no) 2005-12-05
ATE553747T1 (de) 2012-05-15
BRPI0411114B8 (pt) 2021-05-25
JP4871720B2 (ja) 2012-02-08
EA200501789A1 (ru) 2006-06-30
ZA200509222B (en) 2006-09-27
KR100610003B1 (ko) 2006-08-08

Similar Documents

Publication Publication Date Title
ZA200509222B (en) Stable, aqueous solution of human erythropoietin, not containing serum albumin
ATE485835T1 (de) Antikörper enthaltende pharmazeutische lösungen
WO2006020935A3 (en) Stabilizing formulations
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
GT199900072AA (es) Jarabe antihistaminico estabilizado
HRP20110094T8 (en) Solid preparation comprising alogliptin and pioglitazone
MXPA03010640A (es) Composiciones pesticidas liquidas estables.
ATE362314T1 (de) Herbizidzusammensetzungen umfassend imidazolinonsäure
WO2006003371A3 (en) Herbicidal suspension concentrate formulation
EP1930024A3 (en) G-CSF solution formulations having long-term stability
ATE457977T1 (de) Biguanidderivate
DE60316574D1 (de) Stabile augentropfen enthaltend latanoprost als wirkstoff
NO20065791L (no) Asyklovir-formuleringer
AR044449A1 (es) Composiciones acuosas desinfectantes y/o bactericidas
DK1272655T3 (da) Stabilisering af meget fölsomme nucleinsyrefarver i vandig oplösning
WO2004075834A3 (en) Stabilized pharmaceutical compositions of safingol and methods of using the same
CA2545880A1 (en) Erythropoietin solution formulation
ATE424399T1 (de) Pharmazeutische zusammensetzungen von risperidon in wässriger lösung
UY27271A1 (es) Composiciones farmacéuticas
UA90929C2 (ru) Водный гербицидный концентрат суспензии, гербицидное средство и водное гербицидное средство (варианты)
RU2001108785A (ru) Препарат интерферона
ITUD20040162A1 (it) Procedimento di valutazione dell' instabilita' delle proteine contenute in una bevanda a ph acido
CR6305A (es) Formulacion concentrada en suspension que contiene pirimetanilo
TH88612A (th) ยาสำเร็จรูปที่เป็นของเหลวที่ใช้ภายนอกที่มีอินโดเมทธาซิน
MY140071A (en) Stable liquid pesticide compositions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25A Requested transfer of rights approved

Owner name: LG CHEM, LTD. (KR)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF